Karen Aiach, CEO of Lysogene, Winner of the 4th Trophy of the Female Entrepreneurship Co-organ…

PARIS, France and CAMBRIDGE, MA, US – may 12, 2017 – Lysogene (FR0013233475 – LYS), a biopharmaceutical company pioneering and specializing in gene therapy targeting the rare disease of the central nervous system, today announced that Karen Aiach, ceo and Founder, has received the award for Innovation and New Technologies of the Female Entrepreneurship, co-organized by the Association of Female Entrepreneurship and the CPME (the Confederation of Small and Medium-sized Enterprises) for its ” breakthrough, in the closed world of rare diseases. ”

Download the free guide
Boost your gains

It was during a prestigious ceremony which was held at the Council Economic, Social and environment Thursday, 11 may, chaired by François Asselin, President of the CPME, the jury has rewarded the “tenacity of a mother entrepreneur” and appreciated that a ” need family becomes an issue of medical research “.

For François Asselin, ” these awards highlight the women entrepreneurs who know their talent, their initiative, their courage and their tenacity, create, and grow internationally in order to spread entrepreneurship to the French.”

Karen Aiach is delighted : “This award for me goes right to the heart. I dedicate to children suffering from rare diseases and their families, as well as my own family of employees and shareholders who believe in Lysogene. I am proud to lead a company where gender diversity is de rigueur. I will not cease to beat me to that women have the place they deserve in the business world. ”

About the Female Entrepreneurship

The association aims to help and promote female entrepreneurship in France and in the world, and in particular to promote the role of women entrepreneurs in the economic life, or to defend the rights and interests of women entrepreneurs. More information : https://www.eaf-club.com/

About CPME

The CPME (ex-CGPME), the Confederation of Small and Medium-sized Enterprises, is an employers ‘ organisation-professional, private and independent, whose representativeness is already recognised. It ensures the representation and defence of all small and medium-sized enterprises, all sectors (industry, trade, services, crafts), both at the national level, with the public authorities and the social partners, and international levels. It brings together professional associations, trade unions and territorial structures. More information : http://www.cpme.fr/

About Lysogene

Lysogene is a biotechnology corporation clinical stage pioneer in the basic research and the clinical development of gene therapies using vectors derived from adeno-associated viruses to treat rare diseases and life-threatening CNS of the child, for which there is today, to the knowledge of the Company, no treatment. Since 2009, Lysogene has put in place a strong platform and a large network, with innovative products in the MPS-IIIA and in the gangliosidosis GM1. Each of the products developed by Lysogene, LYS-SAF302 and LYS-GM101, has orphan drug designations by the FDA and the EMA, and the designation of rare disease pediatric by the FDA.

Lysogene is listed on the regulated market of Euronext Paris of Euronext Paris (ISIN code : FR0013233475). More information : www.lysogene.com

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply